Anti-CCL2 (Carlumab) -McMMAF
Anti-CCL2 (Carlumab) -McMMAF is an antibody-drug conjugate (ADC) consisting of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab conjugated to the protective group maleimidocaproyl and the tubulin inhibitor MMAF (HY-15579). The ADC toxic molecule and linker part are McMMAF (HY-15578). Anti-CCL2 (Carlumab) -McMMAF induces apoptosis and can be used in cancer research[1][2].
Product Specifications
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Apoptosis; CCR; Microtubule/Tubulin
Related Pathways
Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton; GPCR/G Protein; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[Anti-CCL2(Carlumab)-McMMAF]
References & Citations
[1]Fetterly GJ, et al. Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data. J Clin Pharmacol. 2013 Oct;53 (10) :1020-7.|[2]Tai YT, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15;123 (20) :3128-38.
Shipping Conditions
Room temperature
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
CCR2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040029-100 1x 100 µL
Fibronectin (TV-1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC680994-100 1x 100 µL
TNF alpha (J2D10), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470460-100 1x 100 µL
CD44 Standard (156-3C11), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
